Yuen Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuen Gao has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Xiaodong Zhang
Department of Cancer Research, College of Life Sciences, Nankai University, Tianjin, 300071, China
12 shared publications - Lihong Ye
Department of Biochemistry and Molecular Biology, College of Life Sciences, State Key Laboratory of Medicinal Chemical Biology, Tianjin Key Laboratory of Protein Sciences, Nankai University, Tianjin, China
8 shared publications - Jin He
Department of Biochemistry and Molecular Biology, College of Natural Science, Michigan State University
6 shared publications Zhe Yang
State Key Laboratory of Medicinal Chemical Biology, Department of Cancer Research, College of Life Sciences, Nankai University, Tianjin 300071, China
5 shared publicationsGuang Yang
Department of Cancer Research, College of Life Sciences, Nankai University, Tianjin 300071, China
4 shared publicationsJinyan Feng
Department of Cancer Research, College of Life Sciences, Nankai University, Tianjin 300071, China
4 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by Frontiers Media SA in Frontiers in Child and Adolescent Psychiatry
- Vol. 5, 1900538
The gut microbiome as a modifiable contributor to autism spectrum disorder: a precision gut–immune–brain perspective
Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition characterized by differences in social communication, restricted and repetitive behaviors, sensory processing, and developmental trajectories. Although ASD has a strong genetic and developmental basis, genetics alone does not fully explain the wide variation in symptom severity, gastrointestinal symptoms, immune findings, and response to interventions across individuals. Because many children with ASD also experience gastrointestinal symptoms such as constipation, diarrhea, abdominal pain, reflux, and bloating, recent research has increasingly focused on microbiome-related gut-brain pathways as possible contributors to ASD-related biology (1)(2)(3)(4). However, current evidence does not support framing the gut microbiome as a single cause of ASD. A more cautious and biologically plausible interpretation is that the microbiome represents a modifiable biological system that may interact with genetic susceptibility, environmental exposures, diet, early development, epigenetic regulation, microbial metabolites, and immune signaling.In this Opinion article, we argue that ASD microbiome research may benefit from moving away from broad claims that "gut dysbiosis causes autism" and toward a precision gut-immune-brain framework. Recent human studies with larger sample sizes suggest recurring microbial, metabolic, dietary, and biomarker patterns in ASD, while mechanistic animal studies point to possible pathways involving microbial metabolites, CD4+ T cells, microglia, and neuroinflammation (1,2,5,6). Collectively, these findings are consistent with the idea that microbiome monitoring and targeted microbial interventions may eventually be more useful for biologically defined ASD subgroups than for ASD as a single uniform condition.Because this article is an Opinion article rather than a systematic review, the literature was selected using a narrative approach. We prioritized recent peer-reviewed studies directly relevant to ASD microbiome research, especially human-centered studies with larger cohorts when available, studies examining microbial function or metabolites, and mechanistic work relevant to gut-immune-brain pathways. Selected intervention studies and reviews were also included to evaluate translational potential and limitations. This approach was intended to synthesize emerging themes rather than provide an exhaustive or quantitatively pooled review.Recent high-impact human studies have strengthened the evidence that ASD is associated with altered gut microbial communities and microbial function. Su et al. performed metagenomic sequencing in 1,627 children aged 1-13 years and identified altered archaea, bacteria, fungi, viruses, microbial genes, and metabolic pathways in children with ASD (1). Their multikingdom and functional marker panel achieved strong diagnostic accuracy, suggesting that microbiome-based signatures may eventually contribute to noninvasive biomarker development (1). Similarly, Chen et al. integrated gut metagenomic and metabolomic profiles from more than 1,100 children and identified microbial genomic variants and metabolic shifts associated with ASD, further supporting the importance of microbial function in addition to microbial composition (5). Liu et al. extended this concept by showing that bacterial genomic structural variations in 452 children were associated with ASD and could improve diagnostic modeling beyond bacterial abundance alone (6). Together, these studies suggest that ASD-related microbiome differences are not limited to which microbes are present but may also involve what microbial communities are capable of doing biologically.Most human ASD microbiome studies remain associative. Association indicates that microbial features differ between groups or co-occur with ASD-related traits, but it does not determine whether the microbiome contributes to those traits or reflects diet, gastrointestinal symptoms, medications, or other factors. Mediation would require evidence that microbiome-related changes help explain the relationship between upstream factors, such as diet or immune activation, and downstream behavioral or biological outcomes. Causation requires stronger longitudinal or interventional evidence, which remains limited in humans.Interpretation is further complicated by heterogeneity in ASD cohorts and microbiome methods. Studies vary in diagnostic criteria, ASD severity, cognitive and language profiles, gastrointestinal symptoms, age, sex, medication exposure, and behavioral phenotype. They also differ in stool collection, sequencing platform, bioinformatic pipeline, taxonomic resolution, metabolomic assessment, and statistical adjustment for confounders. Therefore, microbiome findings in ASD should be interpreted as patterns observed within specific cohorts rather than as a universal microbiome signature (2,3,7). Future studies should clearly report how ASD diagnosis was confirmed, such as DSM-based criteria or standardized diagnostic instruments, and should characterize ASD severity, language/cognitive profile, gastrointestinal symptom burden, and medication exposure. These limitations are especially important because ASD is highly heterogeneous, and the microbiome is strongly shaped by diet, family environment, medication use, geography, and gastrointestinal physiology (2). Morton et al. addressed this complexity through a multi-level analysis across microbiome, diet, metabolomic, cytokine, and brain gene-expression datasets, showing that ASDassociated microbial profiles align with broader biological and dietary patterns (2). Notably, siblingmatched cohorts did not show the same architecture as age-and sex-matched cohorts (2). This means microbiome differences may be biologically meaningful, but they are also deeply embedded in environmental and family contexts.An important future direction is to study diet not only as a confounder, but also as an active...
- 19 August 2026
- Published by Frontiers Media SA in Frontiers in Child and Adolescent Psychiatry
- Vol. 5, 1900538
Open AccessThe gut microbiome as a modifiable contributor to autism spectrum disorder: a precision gut–immune–brain perspective
Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition characterized by differences in social communication, restricted and repetitive behaviors, sensory processing, and developmental trajectories. Although ASD has a strong genetic and developmental basis, genetics alone does not fully explain the wide variation in symptom severity, gastrointestinal symptoms, immune findings, and response to interventions across individuals. Because many children with ASD also experience gastrointestinal symptoms such as constipation, diarrhea, abdominal pain, reflux, and bloating, recent research has increasingly focused on microbiome-related gut-brain pathways as possible contributors to ASD-related biology (1)(2)(3)(4). However, current evidence does not support framing the gut microbiome as a single cause of ASD. A more cautious and biologically plausible interpretation is that the microbiome represents a modifiable biological system that may interact with genetic susceptibility, environmental exposures, diet, early development, epigenetic regulation, microbial metabolites, and immune signaling.In this Opinion article, we argue that ASD microbiome research may benefit from moving away from broad claims that "gut dysbiosis causes autism" and toward a precision gut-immune-brain framework. Recent human studies with larger sample sizes suggest recurring microbial, metabolic, dietary, and biomarker patterns in ASD, while mechanistic animal studies point to possible pathways involving microbial metabolites, CD4+ T cells, microglia, and neuroinflammation (1,2,5,6). Collectively, these findings are consistent with the idea that microbiome monitoring and targeted microbial interventions may eventually be more useful for biologically defined ASD subgroups than for ASD as a single uniform condition.Because this article is an Opinion article rather than a systematic review, the literature was selected using a narrative approach. We prioritized recent peer-reviewed studies directly relevant to ASD microbiome research, especially human-centered studies with larger cohorts when available, studies examining microbial function or metabolites, and mechanistic work relevant to gut-immune-brain pathways. Selected intervention studies and reviews were also included to evaluate translational potential and limitations. This approach was intended to synthesize emerging themes rather than provide an exhaustive or quantitatively pooled review.Recent high-impact human studies have strengthened the evidence that ASD is associated with altered gut microbial communities and microbial function. Su et al. performed metagenomic sequencing in 1,627 children aged 1-13 years and identified altered archaea, bacteria, fungi, viruses, microbial genes, and metabolic pathways in children with ASD (1). Their multikingdom and functional marker panel achieved strong diagnostic accuracy, suggesting that microbiome-based signatures may eventually contribute to noninvasive biomarker development (1). Similarly, Chen et al. integrated gut metagenomic and metabolomic profiles from more than 1,100 children and identified microbial genomic variants and metabolic shifts associated with ASD, further supporting the importance of microbial function in addition to microbial composition (5). Liu et al. extended this concept by showing that bacterial genomic structural variations in 452 children were associated with ASD and could improve diagnostic modeling beyond bacterial abundance alone (6). Together, these studies suggest that ASD-related microbiome differences are not limited to which microbes are present but may also involve what microbial communities are capable of doing biologically.Most human ASD microbiome studies remain associative. Association indicates that microbial features differ between groups or co-occur with ASD-related traits, but it does not determine whether the microbiome contributes to those traits or reflects diet, gastrointestinal symptoms, medications, or other factors. Mediation would require evidence that microbiome-related changes help explain the relationship between upstream factors, such as diet or immune activation, and downstream behavioral or biological outcomes. Causation requires stronger longitudinal or interventional evidence, which remains limited in humans.Interpretation is further complicated by heterogeneity in ASD cohorts and microbiome methods. Studies vary in diagnostic criteria, ASD severity, cognitive and language profiles, gastrointestinal symptoms, age, sex, medication exposure, and behavioral phenotype. They also differ in stool collection, sequencing platform, bioinformatic pipeline, taxonomic resolution, metabolomic assessment, and statistical adjustment for confounders. Therefore, microbiome findings in ASD should be interpreted as patterns observed within specific cohorts rather than as a universal microbiome signature (2,3,7). Future studies should clearly report how ASD diagnosis was confirmed, such as DSM-based criteria or standardized diagnostic instruments, and should characterize ASD severity, language/cognitive profile, gastrointestinal symptom burden, and medication exposure. These limitations are especially important because ASD is highly heterogeneous, and the microbiome is strongly shaped by diet, family environment, medication use, geography, and gastrointestinal physiology (2). Morton et al. addressed this complexity through a multi-level analysis across microbiome, diet, metabolomic, cytokine, and brain gene-expression datasets, showing that ASDassociated microbial profiles align with broader biological and dietary patterns (2). Notably, siblingmatched cohorts did not show the same architecture as age-and sex-matched cohorts (2). This means microbiome differences may be biologically meaningful, but they are also deeply embedded in environmental and family contexts.An important future direction is to study diet not only as a confounder, but also as an active...
- Open Access
- 18 June 2026
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 20, 1879968
Editorial: Advancing neurodegenerative disease biomarkers: the role of neuroimaging in TDP-43 and tau proteinopathies
The landscape of neurodegeneration research is undergoing a fundamental transformation, driven by a growing focus on TDP-43 and tau as central, interacting proteinopathies. These proteins recur across multiple neurodegenerative disorders and increasingly appear to act together, amplifying neuronal vulnerability and accelerating disease progression (Youssef et al. 2025). Rather than viewing them as independent entities, the field now recognizes that abnormal proteins often co-occur and may operate along a shared pathological axis (Figure 1). This perspective suggests that TDP-43 and tau influence each other's aggregation dynamics and enhance neurotoxicity, underscoring the importance of clarifying their molecular interplay (Nasir et al.).In parallel, the scope of research is expanding to include additional phenotypic dimensions. Work by Avila-Villanueva et al. highlights sensory dysfunction as an early disease feature. Historically, impairments in smell, taste, and sensory processing were attributed to aging, but evidence now indicates these changes often precede cognitive symptoms. These early alterations may reflect tau deposition within sensory cortices. Recognizing sensory decline as part of the disease continuum enables earlier detection and broadens definitions of onset to include perception and behavior.Neuroimaging advances are reshaping our understanding of disease progression. Diffusion tensor imaging (DTI) reveals that tau pathology can be inferred from microstructural disruption patterns. Detecting subtle changes early is redefining disease timelines and identifying new candidate biomarkers (Costa et al. 2025). Imaging staging systems now classify most patients with tauopathies such as progressive supranuclear palsy and track longitudinal change as shown by Bârlescu et al. More advanced diffusion approaches, including neurite orientation dispersion and density imaging, extend these capabilities further. NODDI provides refined measures of neurite density and organization and is applied across PSP cohorts (Gatto et al. 2024). In amyotrophic lateral sclerosis, exploratory work examined deep gray matter microstructure and identified nominal associations with clinical disability. Although these findings require validation, they underscore sensitivity to early alterations linked to tau and TDP-43.Biomarker discovery is also evolving beyond imaging. Fluid-based measures are now explored as complementary tools capturing disease biology in clinical settings (Li et al. 2024). However, not all candidates ultimately prove informative. A longitudinal study by Aljuhani, examined tumor necrosis factor alpha and receptors across a decade of cerebrospinal fluid data and found no association with progression. These negative findings remain essential for refining hypotheses and emphasize the complexity of neuroinflammatory pathways. These results demonstrate the limitations of relying on single biomarkers and further support integrative strategies.Accordingly, multimodal approaches can combine imaging and fluid measures to provide a broader perspective. Yu et al. integrated diffusion metrics, hippocampal diffusivity, and fluid profiles to characterize progression across healthy controls, mild cognitive impairment, and Alzheimer's disease (AD). Each modality adds a distinct perspective while contributing to a coherent disease trajectory.Diffusion along the perivascular space, reflecting glymphatic function, declines mainly at symptomatic stages. Hippocampal diffusivity captures earlier microstructural changes during mild impairment, whereas fluid markers reveal amyloid depletion and tau accumulation. Together, these combined measures illustrate how multimodal frameworks capture disease evolution across biological and temporal scales.Computational methods add another important dimension.. Machine learning models trained on imaging datasets identify patterns distinguishing tauopathy variants (Braun et al. 2025). However, several challenges remain. Clinical and cognitive measures signal short-term progression, but the rarity of events reduces predictive precision and increases false positives, as shown by Akinwumi et al. Although some models show promise, performance remains insufficient for routine use. These limitations clearly highlight the need for rigorous validation in independent cohorts. Nevertheless, machine learning offers a valuable framework for future precision medicine, especially as datasets become larger and more representative over time.A unifying concept is network-based propagation of proteinopathies. Misfolded proteins such as tau and TDP-43 spread along interconnected neuronal networks. Subcortical regions, including the amygdala and deep gray matter, act as vulnerable hubs facilitating this propagation. The amygdala, with extensive connectivity, serves as a central convergence point for pathological processes. This network architecture may help explain early clinical manifestations (Sharbafshaaer et al.). Microstructural changes in the amygdala relate to fine motor decline, while sensory pathways connect directly to the amygdala and hippocampus, providing a substrate for early deficits (Avila-Villanueva et al.). Advanced neuroimaging now enables mapping of sequential regional changes in vivo, supporting propagation models across disease stages (Bârlescu et al.).As datasets continue to expand and analytical tools improve, new opportunities will emerge to uncover relationships between pathological processes. Cross-disciplinary collaboration becomes increasingly essential, bringing together expertise in imaging, neuropathology, clinical neurology, and data science.Such collaboration supports development of robust biomarkers and reproducible models across diverse populations. Importantly, careful attention to negative findings and methodological limitations strengthens scientific rigor and prevents overinterpretation of preliminary observations. Balanced evaluation...
- 18 June 2026
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 20, 1879968
Open AccessEditorial: Advancing neurodegenerative disease biomarkers: the role of neuroimaging in TDP-43 and tau proteinopathies
The landscape of neurodegeneration research is undergoing a fundamental transformation, driven by a growing focus on TDP-43 and tau as central, interacting proteinopathies. These proteins recur across multiple neurodegenerative disorders and increasingly appear to act together, amplifying neuronal vulnerability and accelerating disease progression (Youssef et al. 2025). Rather than viewing them as independent entities, the field now recognizes that abnormal proteins often co-occur and may operate along a shared pathological axis (Figure 1). This perspective suggests that TDP-43 and tau influence each other's aggregation dynamics and enhance neurotoxicity, underscoring the importance of clarifying their molecular interplay (Nasir et al.).In parallel, the scope of research is expanding to include additional phenotypic dimensions. Work by Avila-Villanueva et al. highlights sensory dysfunction as an early disease feature. Historically, impairments in smell, taste, and sensory processing were attributed to aging, but evidence now indicates these changes often precede cognitive symptoms. These early alterations may reflect tau deposition within sensory cortices. Recognizing sensory decline as part of the disease continuum enables earlier detection and broadens definitions of onset to include perception and behavior.Neuroimaging advances are reshaping our understanding of disease progression. Diffusion tensor imaging (DTI) reveals that tau pathology can be inferred from microstructural disruption patterns. Detecting subtle changes early is redefining disease timelines and identifying new candidate biomarkers (Costa et al. 2025). Imaging staging systems now classify most patients with tauopathies such as progressive supranuclear palsy and track longitudinal change as shown by Bârlescu et al. More advanced diffusion approaches, including neurite orientation dispersion and density imaging, extend these capabilities further. NODDI provides refined measures of neurite density and organization and is applied across PSP cohorts (Gatto et al. 2024). In amyotrophic lateral sclerosis, exploratory work examined deep gray matter microstructure and identified nominal associations with clinical disability. Although these findings require validation, they underscore sensitivity to early alterations linked to tau and TDP-43.Biomarker discovery is also evolving beyond imaging. Fluid-based measures are now explored as complementary tools capturing disease biology in clinical settings (Li et al. 2024). However, not all candidates ultimately prove informative. A longitudinal study by Aljuhani, examined tumor necrosis factor alpha and receptors across a decade of cerebrospinal fluid data and found no association with progression. These negative findings remain essential for refining hypotheses and emphasize the complexity of neuroinflammatory pathways. These results demonstrate the limitations of relying on single biomarkers and further support integrative strategies.Accordingly, multimodal approaches can combine imaging and fluid measures to provide a broader perspective. Yu et al. integrated diffusion metrics, hippocampal diffusivity, and fluid profiles to characterize progression across healthy controls, mild cognitive impairment, and Alzheimer's disease (AD). Each modality adds a distinct perspective while contributing to a coherent disease trajectory.Diffusion along the perivascular space, reflecting glymphatic function, declines mainly at symptomatic stages. Hippocampal diffusivity captures earlier microstructural changes during mild impairment, whereas fluid markers reveal amyloid depletion and tau accumulation. Together, these combined measures illustrate how multimodal frameworks capture disease evolution across biological and temporal scales.Computational methods add another important dimension.. Machine learning models trained on imaging datasets identify patterns distinguishing tauopathy variants (Braun et al. 2025). However, several challenges remain. Clinical and cognitive measures signal short-term progression, but the rarity of events reduces predictive precision and increases false positives, as shown by Akinwumi et al. Although some models show promise, performance remains insufficient for routine use. These limitations clearly highlight the need for rigorous validation in independent cohorts. Nevertheless, machine learning offers a valuable framework for future precision medicine, especially as datasets become larger and more representative over time.A unifying concept is network-based propagation of proteinopathies. Misfolded proteins such as tau and TDP-43 spread along interconnected neuronal networks. Subcortical regions, including the amygdala and deep gray matter, act as vulnerable hubs facilitating this propagation. The amygdala, with extensive connectivity, serves as a central convergence point for pathological processes. This network architecture may help explain early clinical manifestations (Sharbafshaaer et al.). Microstructural changes in the amygdala relate to fine motor decline, while sensory pathways connect directly to the amygdala and hippocampus, providing a substrate for early deficits (Avila-Villanueva et al.). Advanced neuroimaging now enables mapping of sequential regional changes in vivo, supporting propagation models across disease stages (Bârlescu et al.).As datasets continue to expand and analytical tools improve, new opportunities will emerge to uncover relationships between pathological processes. Cross-disciplinary collaboration becomes increasingly essential, bringing together expertise in imaging, neuropathology, clinical neurology, and data science.Such collaboration supports development of robust biomarkers and reproducible models across diverse populations. Importantly, careful attention to negative findings and methodological limitations strengthens scientific rigor and prevents overinterpretation of preliminary observations. Balanced evaluation...
- Open Access
- 10 December 2025
- Published by MDPI AG in Biomedicines
- Vol. 13  (12) , 3025
Pharmacological Interventions in Autism Spectrum Disorder: A Comprehensive Review of Mechanisms and Efficacy
Background and Objectives: Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition characterized by social communication deficits, restricted interests, and repetitive behaviors. At present, there is no pharmacological intervention that reliably targets the core symptoms of ASD; instead, medications are primarily used to manage associated or concurrent symptoms such as irritability, aggression, anxiety, attention difficulties, and sleep disturbances. This review summarizes the current evidence for pharmacological treatments in ASD, emphasizing how these interventions are used in a symptom-focused, adjunctive manner, and highlighting efficacy, mechanisms, limitations, and emerging therapeutic targets. Methods: A comprehensive literature review was conducted across PubMed, Cochrane Library, and Embase to identify clinical trials, systematic reviews, meta-analyses, and preclinical studies on pharmacological interventions for ASD. Seventy-seven references were integrated to reflect the current state of evidence. Results: Established pharmacological strategies include atypical antipsychotics for severe irritability and aggression, as well as antidepressants, stimulants and non-stimulant agents, mood stabilizers, and anxiolytics for selected comorbid symptoms, although efficacy is often modest and variable, and side effects can be significant. Adjunctive and investigational approaches targeting glutamatergic and GABAergic neurotransmission, monoaminergic systems, and neuroinflammatory and oxidative stress pathways show preliminary promise but remain experimental. Across all categories, pharmacological treatments are most effective when embedded in individualized, multimodal care plans that integrate behavioral, rehabilitative, and psychological interventions. Conclusions: This review maps pharmacologic strategies in ASD onto their underlying neurobiological mechanisms and clarifies how evidence strength differs across drug classes and symptom domains. Ongoing advances in genetics, synaptic and circuit-level neuroscience, and neuroimmune signaling are expected to yield more specific, mechanism-based pharmacological approaches for autistic behaviors, with the potential to improve long-term functioning and quality of life when combined with comprehensive psychosocial care.
- 10 December 2025
- Published by MDPI AG in Biomedicines
- Vol. 13  (12) , 3025
Open AccessPharmacological Interventions in Autism Spectrum Disorder: A Comprehensive Review of Mechanisms and Efficacy
Background and Objectives: Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition characterized by social communication deficits, restricted interests, and repetitive behaviors. At present, there is no pharmacological intervention that reliably targets the core symptoms of ASD; instead, medications are primarily used to manage associated or concurrent symptoms such as irritability, aggression, anxiety, attention difficulties, and sleep disturbances. This review summarizes the current evidence for pharmacological treatments in ASD, emphasizing how these interventions are used in a symptom-focused, adjunctive manner, and highlighting efficacy, mechanisms, limitations, and emerging therapeutic targets. Methods: A comprehensive literature review was conducted across PubMed, Cochrane Library, and Embase to identify clinical trials, systematic reviews, meta-analyses, and preclinical studies on pharmacological interventions for ASD. Seventy-seven references were integrated to reflect the current state of evidence. Results: Established pharmacological strategies include atypical antipsychotics for severe irritability and aggression, as well as antidepressants, stimulants and non-stimulant agents, mood stabilizers, and anxiolytics for selected comorbid symptoms, although efficacy is often modest and variable, and side effects can be significant. Adjunctive and investigational approaches targeting glutamatergic and GABAergic neurotransmission, monoaminergic systems, and neuroinflammatory and oxidative stress pathways show preliminary promise but remain experimental. Across all categories, pharmacological treatments are most effective when embedded in individualized, multimodal care plans that integrate behavioral, rehabilitative, and psychological interventions. Conclusions: This review maps pharmacologic strategies in ASD onto their underlying neurobiological mechanisms and clarifies how evidence strength differs across drug classes and symptom domains. Ongoing advances in genetics, synaptic and circuit-level neuroscience, and neuroimmune signaling are expected to yield more specific, mechanism-based pharmacological approaches for autistic behaviors, with the potential to improve long-term functioning and quality of life when combined with comprehensive psychosocial care.
- Open Access
- 15 October 2025
- Published by MDPI AG in Preprints.org
Pharmacological Interventions in Autism Spectrum Disorder: A Comprehensive Review of Mechanisms and Efficacy
Background and Objectives: Autism spectrum disorder (ASD) is a heterogeneous neuro-developmental condition characterized by social communication deficits, restricted interests, and repetitive behaviors. Pharmacological management is challenging given the complex neurobiology and frequent comorbidities. This review summarizes the current evidence for pharmacological treatments in ASD, highlighting efficacy, mechanisms, limitations, and emerging therapeutic targets. Methods: A comprehensive literature review was conducted across PubMed, Cochrane Library, and Embase to identify clinical trials, systematic reviews, meta-analyses, and preclinical studies on pharmacological interventions for ASD. Seventy-seven references were integrated to reflect the state of evidence. Results: Established interventions include antipsychotics such as risperidone and aripiprazole for irritability and aggression, and selective serotonin reuptake inhibitors (SSRIs) for anxiety and repetitive behaviors, though efficacy remains inconsistent. Adjunctive agents targeting glutamatergic, GABAergic, and neuroinflammatory pathways—including memantine, riluzole, minocycline, and N-acetylcysteine—show promise in modulating ex-citatory-inhibitory imbalance and oxidative stress. Novel strategies involving oxytocin, vasopressin, and nanoparticle-based therapies are under early investigation. Conclusions: While current pharmacologic options in ASD remain limited, advances in understanding neurotransmission, immune dysregulation, and neuroplasticity are driving innovation. Personalized approaches integrating biomarkers, genetics, and mechanistic targets may guide the next generation of therapies.
- 15 October 2025
- Published by MDPI AG in Preprints.org
Open AccessPharmacological Interventions in Autism Spectrum Disorder: A Comprehensive Review of Mechanisms and Efficacy
Background and Objectives: Autism spectrum disorder (ASD) is a heterogeneous neuro-developmental condition characterized by social communication deficits, restricted interests, and repetitive behaviors. Pharmacological management is challenging given the complex neurobiology and frequent comorbidities. This review summarizes the current evidence for pharmacological treatments in ASD, highlighting efficacy, mechanisms, limitations, and emerging therapeutic targets. Methods: A comprehensive literature review was conducted across PubMed, Cochrane Library, and Embase to identify clinical trials, systematic reviews, meta-analyses, and preclinical studies on pharmacological interventions for ASD. Seventy-seven references were integrated to reflect the state of evidence. Results: Established interventions include antipsychotics such as risperidone and aripiprazole for irritability and aggression, and selective serotonin reuptake inhibitors (SSRIs) for anxiety and repetitive behaviors, though efficacy remains inconsistent. Adjunctive agents targeting glutamatergic, GABAergic, and neuroinflammatory pathways—including memantine, riluzole, minocycline, and N-acetylcysteine—show promise in modulating ex-citatory-inhibitory imbalance and oxidative stress. Novel strategies involving oxytocin, vasopressin, and nanoparticle-based therapies are under early investigation. Conclusions: While current pharmacologic options in ASD remain limited, advances in understanding neurotransmission, immune dysregulation, and neuroplasticity are driving innovation. Personalized approaches integrating biomarkers, genetics, and mechanistic targets may guide the next generation of therapies.
- Open Access
- 23 August 2024
- Published by Elsevier in Molecular Therapy
- Vol. 32  (9) , 2808-2809
Reversing the path: Mesenchymal-to-mesothelial transition as a novel target in liver fibrosis
- 23 August 2024
- Published by Elsevier in Molecular Therapy
- Vol. 32  (9) , 2808-2809
Open AccessReversing the path: Mesenchymal-to-mesothelial transition as a novel target in liver fibrosis
- Open Access
- 4 May 2023
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 11
Editorial: Hepatitis B virus and host interactions in liver diseases
Editorial: Hepatitis B virus and host interactions in liver diseases
- 4 May 2023
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 11
Open AccessEditorial: Hepatitis B virus and host interactions in liver diseases
Editorial: Hepatitis B virus and host interactions in liver diseases
- Open Access
- 5 April 2022
- Published by Frontiers Media SA in Frontiers in Behavioral Neuroscience
- Vol. 16, 873466
Neural Hyperactivity Is a Core Pathophysiological Change Induced by Deletion of a High Autism Risk Gene Ash1L in the Mouse Brain
ASH1L is one of the highest risk genes associated with autism spectrum disorder (ASD) and intellectual disability (ID). Our recent studies demonstrate that loss of Ash1l in the mouse brain is sufficient to induce ASD/ID-like behavioral and cognitive deficits, suggesting that disruptive ASH1L mutations are likely to have a positive correlation with ASD/ID genesis. However, the core pathophysiological changes in the Ash1l-deficient brain remain largely unknown. Here we show that loss of Ash1l in the mouse brain causes locomotor hyperactivity, high metabolic activity, and hyperactivity-related disturbed sleep and lipid metabolic changes. In addition, the mutant mice display lower thresholds for the convulsant reagent-induced epilepsy and increased neuronal activities in multiple brain regions. Thus, our current study reveals that neural hyperactivity is a core pathophysiological change in the Ash1l-deficient mouse brain, which may function as a brain-level mechanism leading to the Ash1l-deletion-induced brain functional abnormalities and autistic-like behavioral deficits.
- 5 April 2022
- Published by Frontiers Media SA in Frontiers in Behavioral Neuroscience
- Vol. 16, 873466
Open AccessNeural Hyperactivity Is a Core Pathophysiological Change Induced by Deletion of a High Autism Risk Gene Ash1L in the Mouse Brain
ASH1L is one of the highest risk genes associated with autism spectrum disorder (ASD) and intellectual disability (ID). Our recent studies demonstrate that loss of Ash1l in the mouse brain is sufficient to induce ASD/ID-like behavioral and cognitive deficits, suggesting that disruptive ASH1L mutations are likely to have a positive correlation with ASD/ID genesis. However, the core pathophysiological changes in the Ash1l-deficient brain remain largely unknown. Here we show that loss of Ash1l in the mouse brain causes locomotor hyperactivity, high metabolic activity, and hyperactivity-related disturbed sleep and lipid metabolic changes. In addition, the mutant mice display lower thresholds for the convulsant reagent-induced epilepsy and increased neuronal activities in multiple brain regions. Thus, our current study reveals that neural hyperactivity is a core pathophysiological change in the Ash1l-deficient mouse brain, which may function as a brain-level mechanism leading to the Ash1l-deletion-induced brain functional abnormalities and autistic-like behavioral deficits.
- Open Access
- 12 February 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 599, 142-147
SMYD5 is a histone H3-specific methyltransferase mediating mono-methylation of histone H3 lysine 36 and 37
- 12 February 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 599, 142-147
Open AccessSMYD5 is a histone H3-specific methyltransferase mediating mono-methylation of histone H3 lysine 36 and 37
- Open Access
- 18 June 2021
- Published by Springer Nature in Communications Biology
- Vol. 4  (1) , 1-10
Loss of histone methyltransferase ASH1L in the developing mouse brain causes autistic-like behaviors
Autism spectrum disorder (ASD) is a neurodevelopmental disease associated with various gene mutations. Recent genetic and clinical studies report that mutations of the epigenetic gene ASH1L are highly associated with human ASD and intellectual disability (ID). However, the causality and underlying molecular mechanisms linking ASH1L mutations to genesis of ASD/ID remain undetermined. Here we show loss of ASH1L in the developing mouse brain is sufficient to cause multiple developmental defects, core autistic-like behaviors, and impaired cognitive memory. Gene expression analyses uncover critical roles of ASH1L in regulating gene expression during neural cell development. Thus, our study establishes an ASD/ID mouse model revealing the critical function of an epigenetic factor ASH1L in normal brain development, a causality between Ash1L mutations and ASD/ID-like behaviors in mice, and potential molecular mechanisms linking Ash1L mutations to brain functional abnormalities.
- 18 June 2021
- Published by Springer Nature in Communications Biology
- Vol. 4  (1) , 1-10
Open AccessLoss of histone methyltransferase ASH1L in the developing mouse brain causes autistic-like behaviors
Autism spectrum disorder (ASD) is a neurodevelopmental disease associated with various gene mutations. Recent genetic and clinical studies report that mutations of the epigenetic gene ASH1L are highly associated with human ASD and intellectual disability (ID). However, the causality and underlying molecular mechanisms linking ASH1L mutations to genesis of ASD/ID remain undetermined. Here we show loss of ASH1L in the developing mouse brain is sufficient to cause multiple developmental defects, core autistic-like behaviors, and impaired cognitive memory. Gene expression analyses uncover critical roles of ASH1L in regulating gene expression during neural cell development. Thus, our study establishes an ASD/ID mouse model revealing the critical function of an epigenetic factor ASH1L in normal brain development, a causality between Ash1L mutations and ASD/ID-like behaviors in mice, and potential molecular mechanisms linking Ash1L mutations to brain functional abnormalities.